Tirzepatide Initiation in Lithium‐Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real‐World Cohort
Human Psychopharmacology: Clinical and Experimental · 2026
DOI: 10.1002/hup.70066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, 2026. Verfasst von Maria Beatrice Rescalli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Psychiatry, Department of Molecular Medicine, University of Siena School of Medicine, Siena, Italy. Hauptthemen laut MEDLINE: Tirzepatide, Bipolar Disorder, Lithium Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess early renal and lithium‐related safety and 12‐month renal biomarker trajectories after tirzepatide initiation in lithium‐treated adults with bipolar disorder.
Methods
We retrospectively studied 23 adults at one centre. The principal 12‐week renal safety measures were serum creatinine and derived CKD‐EPI 2021 creatinine‐based eGFR. Secondary outcomes included lithium, electrolytes, gastrointestinal symptoms, acute kidney injury meeting KDIGO creatinine criteria and discontinuation. Twelve‐month trajectories and body‐surface‐area‐unindexed eGFR were exploratory.
Results
At 12 weeks, creatinine changed by −3 ± 12 μmol/L ( p = 0.196), indexed eGFR by +2.6 ± 15.1 mL/min/1.73 m 2 ( p = 0.259) and lithium by +0.08 ± 0.17 mmol/L ( p = 0.030). Among 20 on‐treatment completers at 12 months, weight decreased by 17.7 ± 6.0%, creatinine by 12 ± 9 μmol/L, indexed eGFR increased by 13.0 ± 12.1 mL/min/1.73 m 2 and unindexed eGFR by 4.5 ± 14.3 mL/min. Two patients had lithium > 1.2 mmol/L; one developed clinician‐attributed symptomatic toxicity and discontinued tirzepatide. No acute kidney injury meeting KDIGO creatinine criteria could be confirmed from available records.
Conclusions
Co‐prescription warrants structured monitoring and sick‐day education. Creatinine‐based eGFR changes during major weight loss do not establish renal benefit or exclude kidney injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Psychiatry, Department of Molecular Medicine, University of Siena School of Medicine, Siena, Italy.
ORCID-Profile: Maria Beatrice Rescalli, Andrea Fagiolini, Pietro Carmellini, Mario Pinzi
Zitieren
APA
Rescalli, M. B., Fagiolini, A., Carmellini, P., Pinzi, M., Castaldo, F., & Cuomo, A. (2026). Tirzepatide Initiation in Lithium‐Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real‐World Cohort. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.70066
Vancouver
Rescalli MB, Fagiolini A, Carmellini P, Pinzi M, Castaldo F, Cuomo A. Tirzepatide Initiation in Lithium‐Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real‐World Cohort. Human Psychopharmacology: Clinical and Experimental. 2026. doi:10.1002/hup.70066
BibTeX
@article{Rescalli2026,
author = {Rescalli, Maria Beatrice and Fagiolini, Andrea and Carmellini, Pietro and Pinzi, Mario and Castaldo, Flavia and Cuomo, Alessandro},
title = {Tirzepatide Initiation in Lithium‐Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real‐World Cohort},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2026},
doi = {10.1002/hup.70066}
}
EUVIMED